Heart Failure, the Inflammasome, and Interleukin-1β Prognostic and Therapeutic?

被引：7
|
作者：
Everett, Brendan M.
Siddiqi, Hasan K.
机构：
[1] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Med, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 73卷 / 09期
关键词：
biomarkers; heart failure; inflammation; interleukins; NATRIURETIC PEPTIDE; CIRCULATING LEVELS; FAMILY-MEMBER; RISK; ST2; BIOMARKERS; CYTOKINES; RECEPTOR; MARKERS;
D O I：
10.1016/j.jacc.2019.01.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1026 / 1028
页数：3
相关论文
共 50 条
  • [1] Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
    Abbate, Antonio
    Toldo, Stefano
    Marchetti, Carlo
    Kron, Jordana
    Van Tassell, Benjamin W.
    Dinarello, Charles A.
    CIRCULATION RESEARCH, 2020, 126 (09) : 1260 - 1280
  • [2] Targeting Interleukin-1 in Heart Failure and Inflammatory Heart Disease
    Van Tassell B.W.
    Raleigh J.M.V.
    Abbate A.
    Current Heart Failure Reports, 2015, 12 (1) : 33 - 41
  • [3] Interleukin-1, inflammasome and autoinflammatory diseases
    Jamilloux, Y.
    Bourdonnay, E.
    Gerfaud-Valentin, M.
    Py, B. F.
    Lefeuvre, L.
    Barba, T.
    Broussolle, C.
    Henry, T.
    Seve, P.
    REVUE DE MEDECINE INTERNE, 2018, 39 (04): : 233 - 239
  • [4] Hepatic inflammasome activation as origin of Interleukin-1α and Interleukin-1β in liver cirrhosis
    Praktiknjo, Michael
    Schierwagen, Robert
    Monteiro, Sofia
    Ortiz, Cristina
    Uschner, Frank Erhard
    Jansen, Christian
    Claria, Joan
    Trebicka, Jonel
    GUT, 2021, 70 (09) : 1799 - 1800
  • [5] Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure
    Jafree, Ehsan
    Del Buono, Marco Giuseppe
    Canada, Justin M.
    Carbone, Salvatore
    Kron, Jordana
    Arena, Ross
    Van Tassell, Benjamin
    Abbate, Antonio
    Trankle, Cory R.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2024, 83 (06) : 522 - 530
  • [6] Beyond Remodeling: Interleukin-1 Blockade as a Therapeutic Strategy to Prevent Heart Failure After Myocardial Infarction
    Golino, Michele
    Morello, Matteo
    JACC-HEART FAILURE, 2024, 12 (10) : 1800 - 1801
  • [7] Interleukin-1 (IL-1) and the inflammasome in cancer
    Pretre, Vincent
    Papadopoulos, Dimitrios
    Regard, Jean
    Pelletier, Marc
    Woo, Janghee
    CYTOKINE, 2022, 153
  • [8] INTERLEUKIN-1 AS A THERAPEUTIC TARGET
    TRACEY, D
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 29, 1994, 29 : 205 - 214
  • [9] Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
    Potere, Nicola
    Del Buono, Marco Giuseppe
    Caricchio, Roberto
    Cremer, Paul C.
    Vecchie, Alessandra
    Porreca, Ettore
    Dalla Gasperina, Daniela
    Dentali, Francesco
    Abbate, Antonio
    Bonaventura, Aldo
    EBIOMEDICINE, 2022, 85
  • [10] ROLE OF INTERLEUKIN-1 AND THE THERAPEUTIC POTENTIAL OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN SEPSIS
    FISHER, CJ
    OPAL, SM
    LOWRY, SF
    SADOFF, JC
    LABRECQUE, JF
    DONOVAN, HC
    LOOKABAUGH, JL
    LEMKE, J
    PRIBBLE, JP
    STROMATT, SC
    VIGERS, GP
    RUSSELL, DA
    THOMPSON, RC
    CIRCULATORY SHOCK, 1994, 44 (01) : 1 - 8
12345